Literature DB >> 9288159

Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate.

J C Watson1, J G Redmann, M O Meyers, R C Alperin-Lea, B M Gebhardt, J B Delcarpio, E A Woltering.   

Abstract

BACKGROUND: Recurrence and mortality rates in patients with breast cancer correlate with the degree of tumor angiogenesis (angiogenic index). We have developed a novel angiogenesis model by using disks of fresh human placental vein that initiate an angiogenic response and exhibit linear radial capillary growth in culture. We hypothesized that the addition of human breast cancer cells to this human placental vein angiogenesis model would increase the incidence of angiogenesis and accelerate the rate of neovessel growth compared with vein disk cultured without tumor cells.
METHODS: To test this hypothesis, vein explants from seven human placentas were incorporated into clots of 0.3% fibrin in Medium 199 and fetal bovine serum with or without 1.5 x 10(5) T-47D (n = 6 placentas) or MCF-7 (n = 1 placenta) breast cancer cells. Statistical differences between the experimental (with breast cancer cells) and control (no added cells) cultures were determined by repeated measures ANOVA.
RESULTS: The proportion of disks exhibiting neovessel growth (initiation) by day 12 was significantly increased in the presence of T-47D cells (p < 0.05 at day 12, p < 0.001 at day 15). No statistical difference was seen in rates of neovessel growth (millimeters per day). Similar results were seen with MCF-7 cells.
CONCLUSIONS: Tumor enhancement of angiogenesis may occur by increased initiation of the angiogenic response. Subsequent vessel growth rates may be tumor independent. We predict that effective antiangiogenic therapies will block a tumor's ability to augment angiogenesis initiation rather than subsequent neovessel growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288159     DOI: 10.1016/s0039-6060(97)90045-3

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Metronomic dosing enhances the anti-angiogenic effect of epothilone B.

Authors:  Mark W Stalder; Catherine T Anthony; Eugene A Woltering
Journal:  J Surg Res       Date:  2009-12-30       Impact factor: 2.192

2.  A study of pipeline drugs in neuroendocrine tumors.

Authors:  Catherine T Anthony; Juan G Bastidas; Jessica L Thomson; John Lyons; James M Lewis; Joshua E Schwimer; Peter Casey; Jennifer Abadie; Daniel J Frey; Yi-Zarn Wang; J Philip Boudreaux; Eugene A Woltering
Journal:  J Gastrointest Cancer       Date:  2012-06

3.  Pericytes on the tumor vasculature: jekyll or hyde?

Authors:  Keith D Barlow; Anne M Sanders; Shay Soker; Suleyman Ergun; Linda J Metheny-Barlow
Journal:  Cancer Microenviron       Date:  2012-03-31

4.  Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs.

Authors:  Eugene A Woltering; James M Lewis; P Johnstone Maxwell; Daniel J Frey; Yi-Zarn Wang; John Rothermel; Catherine T Anthony; Douglas A Balster; J Patrick O'Leary; Lynn H Harrison
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

5.  An assay to measure angiogenesis in human fat tissue.

Authors:  Frank L Greenway; Zhijun Liu; Ying Yu; Mary K Caruso; Andrew T Roberts; John Lyons; Joshua E Schwimer; Alok K Gupta; Drake E Bellanger; Thomas S Guillot; Eugene A Woltering
Journal:  Obes Surg       Date:  2007-04       Impact factor: 4.129

6.  Tumor-induced loss of mural Connexin 43 gap junction activity promotes endothelial proliferation.

Authors:  Mayur Choudhary; Christine Naczki; Wenhong Chen; Keith D Barlow; L Douglas Case; Linda J Metheny-Barlow
Journal:  BMC Cancer       Date:  2015-05-23       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.